Mobile stroke units have been shown to accelerate patient evaluation and treatment. Now, for the first time, this speedier management has been shown to translate to clinical benefit for patients.
Mobile stroke units are gaining significant traction in the U.S. and around the world. A new paper looks back on the units’ time-to-treatment effects — and ahead to outcome and cost impacts.
A study on Cleveland Clinic’s mobile stroke unit reveals one characteristic that seems to particularly drive early IV thrombolysis delivery.
Practice may not make perfect in healthcare, but it can sure make for greater efficiency and effectiveness. This study of our mobile stroke unit’s evolution over three years is a case in point.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A Cleveland Clinic study presented at the 2018 International Stroke Conference suggests these units may help bypass interhospital transfers for patients requiring thrombectomy.
The newly published DEFUSE 3 trial joins the DAWN trial in support of extending the time window for endovascular thrombectomy in selected patients with acute ischemic stroke.
Something’s going right in acute stroke therapy: Medicare data show that one-year mortality fell 18 percent from 2009 to 2013 in tandem with a 60 percent rise in IV tPA use.
A slew of randomized trials have confirmed the superiority of endovascular therapy over IV t-PA alone for acute ischemic stroke. Here’s how endovascular therapies can be best deployed to yield the greatest patient benefits.
Cleveland Clinic’s care path guide for acute ischemic stroke provides comprehensive protocols for evaluation and management of patients during the acute stroke phase. The Stroke Care Path focuses on the period from initial hospital presentation to 90 days after discharge, a time span critical to successful rehabilitation.